Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary
Compounding Law; Health Care; Awareness of all Types of Compounding Issues;
Pharmacy Benefit Managers (PBMs), Outsourcing Facilities
Food and Drug Administration and Compliance Issues
Monday, April 20, 2020
The Path Forward: Coronavirus Treatment Acceleration Program
The coronavirus (COVID-19) pandemic is an unprecedented event in modern history and has required an extraordinary response around the world. As is true with any public health emergency, there’s tremendous interest among all parties to identify and implement potential short- and long-term solutions.
Quickly after the emergence of this virus, the U.S. Food and Drug Administration began working directly with federal health partners, academia and industry to advance medical countermeasures against COVID-19. Given the urgent nature of the pandemic, the FDA launched a new program called the Coronavirus Treatment Acceleration Program (CTAP) to move new treatments to patients as soon as possible, while at the same time finding out whether they are helpful or harmful. So far, 72 clinical trials of potential therapies for COVID-19 are underway with FDA oversight.